These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. Collen D; Lijnen HR; Todd PA; Goa KL Drugs; 1989 Sep; 38(3):346-88. PubMed ID: 2509190 [TBL] [Abstract][Full Text] [Related]
46. [Thrombolytic therapy in acute myocardial infarction. Mechanism of action and treatment considerations]. Roguin A; Manaster J; Roguin N Harefuah; 1993 Jun; 124(12):770-5. PubMed ID: 8375772 [No Abstract] [Full Text] [Related]
49. Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. Gibson CM; Cannon CP; Piana RN; Breall JA; Sharaf B; Flatley M; Alexander B; Diver DJ; McCabe CH; Flaker GC J Am Coll Cardiol; 1995 Mar; 25(3):582-9. PubMed ID: 7860900 [TBL] [Abstract][Full Text] [Related]
50. Is the use of t-PA as compared with streptokinase cost effective? Rose EA N Engl J Med; 1995 Oct; 333(15):1009; author reply 1010. PubMed ID: 7666904 [No Abstract] [Full Text] [Related]
51. [Thrombolytic therapy in acute myocardial infarct]. Bode C; Baumann H; von Hodenberg E; Kübler W Med Klin (Munich); 1992 Feb; 87(2):64-9. PubMed ID: 1542285 [No Abstract] [Full Text] [Related]
52. Safe use of thrombolysis in the elderly. Wittry MD; Thornton TA; Chaitman BR Geriatrics; 1989 Nov; 44(11):28-30, 33-6. PubMed ID: 2509296 [TBL] [Abstract][Full Text] [Related]
53. Medical audit and formulary management: a policy for rational use of thrombolytic drugs. Morgan DJ; Sutters CA; Pugh S Postgrad Med J; 1991 Feb; 67(784):165-9. PubMed ID: 1904156 [TBL] [Abstract][Full Text] [Related]
54. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator]. Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348 [TBL] [Abstract][Full Text] [Related]
55. Comparison of the thrombolytic activity of the novel plasminogen activator, LY210825, to anisoylated plasminogen-streptokinase activator complex in a canine model of coronary artery thrombolysis. Jackson CV; Frank JD; Craft TJ; Sundboom JL; Smith GF J Pharmacol Exp Ther; 1992 Jan; 260(1):64-70. PubMed ID: 1731052 [TBL] [Abstract][Full Text] [Related]
56. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC). Johnson ES; Cregeen RJ Drugs; 1987; 33 Suppl 3():298-311. PubMed ID: 3315612 [TBL] [Abstract][Full Text] [Related]
57. Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction. Julian DG; Borthwick LS; Reid D; Jennings KP; Wainwright RJ; Rodger JC; Wood D; Phillips WS Drugs; 1987; 33 Suppl 3():261-7. PubMed ID: 3315604 [TBL] [Abstract][Full Text] [Related]
59. [Myocardial infarction treated within 4 hrs: comparison of the cost-benefit ratio of 3 thrombolytic treatments: APSAC, rt-PA and streptokinase in 270 patients]. Machecourt J; Cassagnes J; Bassand JP; Dumoulin J; Calop J; Foroni L; Terrisse MP; Hénon T; Petit L; Denis B Arch Mal Coeur Vaiss; 1993 Feb; 86(2):209-17. PubMed ID: 8363422 [TBL] [Abstract][Full Text] [Related]
60. Is the use of t-PA as compared with streptokinase cost effective? Armentano R; Favaloro RG N Engl J Med; 1995 Oct; 333(15):1009-10. PubMed ID: 7666905 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]